Virtual Library

Start Your Search

Ramón Ortiz Carrodeguas



Author of

  • +

    P2.01 - Advanced NSCLC (ID 159)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.01-33 - Survival Benefit of Depleting High Serum EGF Concentration in Advanced NSCLC Patients as Switch Maintenance Therapy (Now Available) (ID 1931)

      10:15 - 18:15  |  Author(s): Ramón Ortiz Carrodeguas

      • Abstract
      • Slides

      Background

      Background: Serum EGF depleting immunotherapy (EDIT) with CIMAvax-EGF has shown to be safe and effective in the treatment of advanced NSCLC patients after first line of treatment with platinum based chemotherapy. The rationale of its use is to create an immune response against circulating serum EGF and by doing this prevent its binding to EGFR. Previous studies have shown that serum EGF levels above 870 pg/mL and response to chemotherapy (at least stable disease) are independent predictors of the response to EDIT. In this study we aimed to better estimate the benefit of this therapy in the population of first line responders with high basal serum EGF concentration

      Method

      To know the benefit of EDIT in overall survival compared to Best Support Care in this selected population, we pooled data data from three late stage clinical trials of CIMAvax-EGF in patients with advanced NSCLC (IC RD-EC056, IC RD-EC081, and IC RD-EC0120) after First Line Platinum based chemotherapy. The main outcome was overall survival.

      Result

      Out of 523 patients included in the study, 484 were responders (at least stable disease) to FLC. sEGF concentration above 870 pg/mL was measured in 106 patients, (74 and 32 in the EDIT and Control group, respectively). All 106 patients carrying these two protective distinctive features were included in the analyses. A significant benefit in median overall survival was found (14.6 m vs 9.6 m, p=0.001; 5 y survival rate: 22% vs 3%) favouring EDIT therapy.

      imagen1.png

      Conclusion

      EGF Depleting Immunotherapy (EDIT) induces a survival benefit as Switch Maintenance in avanced NSCLC patients with high serum EGF concentration.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.